PA
VRDN icon

Parallel Advisors’s Viridian Therapeutics VRDN Stock Holding History

Parallel Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.19K Sell
65
-18
-22% -$290 ﹤0.01% 3649
2026
Q1 		$1.62K Buy
83
+18
+28% +$535 ﹤0.01% 3434
2025
Q4 		$2.02K Hold
65
– – ﹤0.01% 3127
2025
Q3 		$1.4K Hold
65
– – ﹤0.01% 3137
2025
Q2 		$909 Buy
+65
New +$882 ﹤0.01% 3213
2025
Q1 		– Sell
-10
Closed -$192 – 3681
2024
Q4 		$192 Sell
10
-18
-64% -$391 ﹤0.01% 3378
2024
Q3 		$637 Buy
+28
New +$458 ﹤0.01% 3139

Other funds holding VRDN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Parallel Advisors's VRDN Position: Q2 2026 in Review

Parallel Advisors reduced its Viridian Therapeutics (VRDN) stake by 22% in Q2 2026, selling an estimated $290 and leaving 65 shares worth $1.19K. The position accounts for ﹤0.01% of the portfolio, ranked #3649.

Parallel Advisors first reported a position in VRDN in Q3 2024 and has held it in 7 quarters since. The position peaked at $2.02K in Q4 2025. 65 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Parallel Advisors held 65 shares of Viridian Therapeutics worth $1.19K as of Q2 2026.
  • Parallel Advisors sold 18 Viridian Therapeutics shares in Q2 2026, an estimated $290.
  • Viridian Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3649 holding.
  • Parallel Advisors first reported a position in Viridian Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Parallel Advisors's Viridian Therapeutics position peaked at $2.02K in Q4 2025.
  • 65 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.